Compare Novo Nordisk A/S (NVO) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs ProShares Ultra QQQ ETF — how do they compare? Novo Nordisk A/S trades at $38.38 (market cap $165.31B), while ProShares Ultra QQQ ETF trades at $98.27 (market cap $15.38B). The key difference: Novo Nordisk A/S is far larger — about 10.7× ProShares Ultra QQQ ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while ProShares Ultra QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and ProShares Ultra QQQ ETF for 37 Days on average.
| NVO | QLD | |
|---|---|---|
Market Cap | $165.31B | $15.38B |
Volume | 11,432,838 | 4,844,085 |
Sector | Health | Leveraged / Inverse |
52-Week High | $63.98 | $100.77 |
52-Week Low | $35.29 | $57.16 |
Typical Hold Time | 116 Days | 37 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
QLD (ProShares Ultra QQQ ETF) trades at $98.12, down 2.11% on the day. Technical indicators show a bullish trend with moving averages supporting upside momentum while oscillators remain neutral. The ETF benefits from 2x leverage on the Nasdaq-100, providing amplified exposure to large-cap tech stocks. Recent institutional buying and media coverage highlight continued investor interest in leveraged tech exposure.
Outlook remains cautiously optimistic given the bullish technical setup and institutional accumulation, though leveraged ETFs carry elevated volatility risks during market downturns. The key opportunity lies in continued tech sector strength, while the primary risk involves amplified losses if the Nasdaq-100 declines significantly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
